← Catalyst calendarONCY biotech catalysts & pipeline
ONCOLYTICS BIOTECH INC · Data as of 2026-10-13
Upcoming catalysts
pelareorep — Initial data
Late 2026
The Company believes this approach provides the opportunity to generate early randomized efficacy data from Part A while simultaneously positioning Part B as a potential registrational study without the need to initiate a separate registrational trial. It also expects to report an initial tumor response update from patients enrolled in Part A by year-end 2026 and, subject to FDA feedback, initiate enrollment in Part B of the study during the first quarter of 2027.
Source filingpelareorep — Conference presentation
2026
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026
Source filingpelareorep — Interim data
H2 2026
In the first quarter of 2026, we made the determination that we had sufficient patients enrolled in Cohort 5 that would allow us to properly analyze the combinations being tested in the cohort. We expect to present preliminary analysis of the data in the second half of 2026 once survival data has matured sufficiently.
Source filingExplore the free biotech catalyst calendar
